Drugs / Tissue Engineered Vagina
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05675722 | Jun 2023 → Dec 2029 expected | mullerian aplasia | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tissue Engineered Vagina | “The final Tissue Engineered Vagina (TEV) is implanted into the native vaginal site” NCT05675722 ↗ |
| Known as | TEV | “The final Tissue Engineered Vagina (TEV) is implanted into the native vaginal site” NCT05675722 ↗ |
| Modality | Cell therapy | “Vulvar/vaginal Smooth muscle cells (SMC) and Epithelial Cells (EPC) are isolated from autologous patient's biopsy” NCT05675722 ↗ |
| Route | Other | “Biologic vaginal construct, surgically implanted into native vaginal site” NCT05675722 ↗ |